3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
OBJECTIVES:
Primary
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer.
Secondary
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment.
OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography imaging procedures.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: 3'-deoxy-3'-[18F]fluorothymidine The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. |
Device: 3'-deoxy-3'-[18F]fluorothymidine
The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs [at time of PET or CT PET Scan]
- Changes in thymidine kinase, thymidylate synthase, and standardized uptake values [before and after therapy]
Secondary Outcome Measures
- FLT PET response rate [up to 2 hours during PET scan]
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Meets one of the following criteria:
-
Histologically confirmed solid tumor or hematologic malignancy
-
Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or standard imaging
PATIENT CHARACTERISTICS:
-
Able to lie still in the PET scanner
-
Girth and weight must be suitable to enter the gantry
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- Not specified
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Barbara Ann Karmanos Cancer Institute | Detroit | Michigan | United States | 48201-1379 |
Sponsors and Collaborators
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Anthony F. Shields, MD, PhD, Barbara Ann Karmanos Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 2006-127
- P30CA022453
- WSU-2006-127